Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% – Should You Sell?

Cue Biopharma, Inc. (NASDAQ:CUE) shares fell 3.8% on Monday . The stock traded as low as $24.80 and last traded at $26.10. 315,940 shares traded hands during trading, an increase of 85% from the average daily volume of 170,606 shares. The stock had previously closed at $27.12.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CUE shares. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen raised Cue Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Cue Biopharma Trading Down 3.8%

The stock’s fifty day moving average is $29.31 and its two-hundred day moving average is $154.54. The firm has a market cap of $109.62 million, a P/E ratio of -4.67 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($3.30) by $2.22. The firm had revenue of $5.69 million during the quarter, compared to analyst estimates of $2.50 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Institutional Trading of Cue Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd bought a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $389,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cue Biopharma in the second quarter worth approximately $722,000. BlackRock Inc. purchased a new stake in Cue Biopharma in the second quarter valued at approximately $1,824,000. Northwestern Mutual Wealth Management Co. lifted its position in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Cue Biopharma in the 3rd quarter worth approximately $62,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.